Stocks · News reference
Dianthus Therapeutics Announces New Pipeline Candidate, DNTH312 for Autoimmune Disorders; The Company Expects DNTH312 to be Phase 1 Ready By End Of 2027
DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanismsDNTH312 demonstrated
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $130 to $158.
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.